Literature DB >> 9339681

The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia.

D Lorenzetti1, S Bohlega, H Y Zoghbi.   

Abstract

The autosomal dominant spinocerebellar ataxias (ADSCAs) are a heterogeneous group of late-onset neurodegenerative disorders with overlapping clinical features. Genetic linkage studies have identified at least seven distinct loci for the ADSCAs, allowing the genetic classification of these disorders. The spinocerebellar ataxia type 2 (SCA2) locus was mapped to chromosome 12, and a gene responsible for this disorder was recently isolated. The mutation causing SCA2 is an expansion of a trinucleotide CAG repeat contained within the coding region of a novel gene. We describe the results of genotypic analysis for the SCA2 repeat in individuals with ADSCA who were previously found negative for CAG repeat expansions in the SCA1, SCA3, or SCA6 genes. The expanded CAG repeat has been identified in 15 independent families. Repeat instability and anticipation were observed in two large kindreds. The SCA2 mutation was found in 18% of our ADSCA kindreds, confirming the high proportion of SCA2 among this group of disorders.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9339681     DOI: 10.1212/wnl.49.4.1009

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Selective Forces Related to Spinocerebellar Ataxia Type 2.

Authors:  Lucas Schenatto Sena; Raphael Machado Castilhos; Eduardo Preusser Mattos; Gabriel Vasata Furtado; José Luiz Pedroso; Orlando Barsottini; Maria Marla Paiva de Amorim; Clecio Godeiro; Maria Luiza Saraiva Pereira; Laura Bannach Jardim
Journal:  Cerebellum       Date:  2019-04       Impact factor: 3.847

Review 2.  Relation Between Stress Granules and Cytoplasmic Protein Aggregates Linked to Neurodegenerative Diseases.

Authors:  Ioana Dobra; Serhii Pankivskyi; Anastasiia Samsonova; David Pastre; Loic Hamon
Journal:  Curr Neurol Neurosci Rep       Date:  2018-11-08       Impact factor: 5.081

Review 3.  Biology and Pathobiology of TDP-43 and Emergent Therapeutic Strategies.

Authors:  Lin Guo; James Shorter
Journal:  Cold Spring Harb Perspect Med       Date:  2017-09-01       Impact factor: 6.915

Review 4.  Small GTPases in C. elegans metabolism.

Authors:  Daniel Z Bar; Chayki Charar; Yosef Gruenbaum
Journal:  Small GTPases       Date:  2016-11-18

5.  Epigenetics DNA methylation in the core ataxin-2 gene promoter: novel physiological and pathological implications.

Authors:  José Miguel Laffita-Mesa; Peter O Bauer; Vivian Kourí; Leodani Peña Serrano; Jane Roskams; Dennis Almaguer Gotay; Julio Cesar Montes Brown; Pedro Ariel Martínez Rodríguez; Yanetza González-Zaldívar; Luís Almaguer Mederos; Dany Cuello-Almarales; Jorge Aguiar Santiago
Journal:  Hum Genet       Date:  2011-10-30       Impact factor: 4.132

6.  Ataxin-2 intermediate-length polyglutamine expansions in European ALS patients.

Authors:  Teresa Lee; Yun R Li; Caroline Ingre; Markus Weber; Torsten Grehl; Ole Gredal; Mamede de Carvalho; Thomas Meyer; Ole-Björn Tysnes; Georg Auburger; Suzana Gispert; Nancy M Bonini; Peter M Andersen; Aaron D Gitler
Journal:  Hum Mol Genet       Date:  2011-02-03       Impact factor: 6.150

7.  ALS-associated ataxin 2 polyQ expansions enhance stress-induced caspase 3 activation and increase TDP-43 pathological modifications.

Authors:  Michael P Hart; Aaron D Gitler
Journal:  J Neurosci       Date:  2012-07-04       Impact factor: 6.167

8.  Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis.

Authors:  Juan Crespo-Barreto; John D Fryer; Chad A Shaw; Harry T Orr; Huda Y Zoghbi
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

Review 9.  The clinical trial landscape in amyotrophic lateral sclerosis-Past, present, and future.

Authors:  Heike J Wobst; Korrie L Mack; Dean G Brown; Nicholas J Brandon; James Shorter
Journal:  Med Res Rev       Date:  2020-02-11       Impact factor: 12.944

10.  Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS.

Authors:  Andrew C Elden; Hyung-Jun Kim; Michael P Hart; Alice S Chen-Plotkin; Brian S Johnson; Xiaodong Fang; Maria Armakola; Felix Geser; Robert Greene; Min Min Lu; Arun Padmanabhan; Dana Clay-Falcone; Leo McCluskey; Lauren Elman; Denise Juhr; Peter J Gruber; Udo Rüb; Georg Auburger; John Q Trojanowski; Virginia M-Y Lee; Vivianna M Van Deerlin; Nancy M Bonini; Aaron D Gitler
Journal:  Nature       Date:  2010-08-26       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.